All In Biotech

Drug Trial Radar · NCT05053880

A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

A Phase 1b/2a Study of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Sep 22, 2021

Primary completion

Oct 25, 2024

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Accendatech USA Inc.Industry
Sponsor type
Industry
Collaborators
C3 Research Associates; Avance Clinical Pty Ltd.
First posted
Sep 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The current design provides a window to analyze the impact of the ACT001+Pembrolizumab combination on the tumor microenvironment and disease outcomes.

Conditions

  • Recurrent Glioblastoma Multiforme(GBM)

Interventions

  • ACT001Drug

    Phase1b - Starting approximately 2 weeks prior to the scheduled surgery, patient will receive an assigned dose of ACT001 by mouth in combination with a single dose of 200 mg pembrolizumab via an intravenous (IV-through a tube in vain) infusion in the clinic. Then patient will self administer ACT001 capsules twice daily by mouth, at the dose to which patient is assigned, until the evening prior to scheduled surgery. Patient will then undergo surgery to remove all or part of tumor. This a standard 3+3 dose escalation.

  • ACT001 + PembrolizumabDrug

    Phase 2a - Starting approximately 2 weeks prior to the scheduled surgery, patient will receive a single dose of 200 mg pembrolizumab via an intravenous (IV) infusion in the clinic (an IV infusion means the drug will be delivered through a tube in your vein). Patient will then self-administer ACT001 capsules twice daily by mouth, at the dose to which patient is assigned, until the evening prior to scheduled surgery. Patient then will undergo surgery to remove all or part of tumor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1b-Incidence, type and severity of treatment-emergent AEs (TEAEs)Time frame: Approximately 7 months. Each cycle is 21 days; from start of first dose with investigational product until completion of the last study related procedure (including follow-up for safety assessments- 30days after last dose)
  2. 1b-Dose limiting toxicities (DLTs)Time frame: From first dose of study therapy until the end of the first post-surgery cycle (Cycle 1, Day 21).
  3. 1b-Mean changes in vital sign measurements-Heart RateTime frame: Approximately 8months/ patient. Each cycle is 21 days. Start at screening, Pre-surgical Treatment Period, Cycle 1 and each subsequent Cycle and 30 days after last dose
  4. 1b-Mean changes in vital sign measurements- supine blood pressureTime frame: Approximately 8months/ patient.Each cycle is 21 days. Start at screening, Pre-surgical Treatment Period, Cycle 1 and each subsequent Cycle and 30 days after last dose
  5. 1b-Mean changes in vital sign measurements- body temperatureTime frame: Approximately 8months/ patient. Each cycle is 21 days. Start at screening, Pre-surgical Treatment Period, Cycle 1 and each subsequent Cycle and 30 days after last dose
  6. 1b-Mean changes in vital sign measurements- respiratory rateTime frame: Approximately 8months/ patient. Each cycle is 21 days. Start at screening, Pre-surgical Treatment Period, Cycle 1 and each subsequent Cycle and 30 days after last dose
  7. 1b-Mean changes in electrocardiogram (ECG) parametersTime frame: approximately 8months/patient. Each cycle is 21 days. Start at screening, Pre-surgical Treatment Period, Cycle 1 and each subsequent Cycle and 30 days after last dose
  8. 1b-Mean changes in Karnofsky Performance Scale scoreTime frame: Approximately 8 months/patient. Each cycle is 21 days. Start at screening, Pre-surgical Treatment Period, Cycle 1 and each subsequent Cycle and 30 days after last dose
  9. 2a-Progression free survival (PFS) at 6 monthsTime frame: Six months after initiation of study therapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UT MD Anderson Cancer Center, Dept of Neuro-Oncology

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.